The increase in gross profit was driven by the increase in net sales, which was partially offset by the increase in higher salary and related benefits costs from overtime and the addition of a second shift to meet increased demand. Furthermore, increased scrap during quality inspections also negatively impacted gross profit and the gross margin. In January 2018, we implemented a nondestructive testing protocol to reduce scrap.

Andy Sealfon, RMS Chief Executive Officer commented, "I am so pleased to announce that due to the outstanding performance and expanded market acceptance of our FREEDOM Syringe Infusion System, as well as the confirmation by the FDA of the unique technology supporting the use of our system for subcutaneous medications including Hizentra® and Cuvitru®, as well as for intravenous uses such as antibiotics, we experienced our best year ever in the Company's history for net sales and profitability. With new markets opening, planned introduction of new products this year, multiple new clinical trials underway, and international market expansions, we believe we are well positioned for future growth."

For consistency in disclosure presented in our Form 10-K for the period ending December 31, 2017 as required by SEC regulations, we are providing a presentation of the ten months ending December 31, 2017 versus twelve months ending February 28, 2017 as a result of our fiscal year end change. The variations in this presentation are due to the comparison of a ten month period versus a twelve month period. However, net sales in the ten month period were higher than the twelve month period, also due to volume increases with our existing customers domestically and internationally in all major product categories for the same reasons stated above. See Selected Financial Results attached.

About RMS Medical Products

The Company manufactures medical products used for home infusions and suctioning. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.

The Company's website may be visited at www.rmsmedicalproducts.com.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms term "believe" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. The results of operations for the periods presented herein are not necessarily indicative of the results to be expected in the future.

For more information, please call:

Mike King
702 650 3000
Princeton Research


SELECTED FINANCIAL RESULT


For the Three Months Ended December 31, 2017 2016 NET SALES $ 4,125,480 $ 2,871,142 Cost of goods sold 1,635,284 1,080,513 Gross Profit 2,490,196 1,790,629 OPERATING EXPENSES Selling, general and administrative 2,057,616 1,742,701 Research and development 3,023 52,315 Depreciation and amortization 77,383 83,794 Total Operating Expenses 2,138,022 1,878,810 Net Operating Profit/(Loss) 352,174 (88,181 ) Non-Operating (Income)/Expense Interest expense — 1,930 (Income)/loss on foreign currency exchange (3,487 ) 46,820 Other expense and interest income, net (1,316 ) (323 ) INCOME (LOSS) BEFORE TAXES 356,977 (136,608 ) Income Tax (Expense) Benefit (78,607 ) 46,116 NET INCOME (LOSS) $ 278,370 $ (90,492 ) NET INCOME (LOSS) PER SHARE Basic $ 0.01 $ 0.00 Diluted $ 0.01 $ 0.00 WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic 37,994,298 37,754,723 Diluted 38,649,178 37,802,342

SELECTED FINANCIAL RESULTS


For the Twelve Months Ended December 31, 2017 2016 NET SALES $ 15,442,712 $ 12,364,285 Cost of goods sold 6,174,605 4,683,390 Gross Profit 9,268,107 7,680,895 OPERATING EXPENSES Selling, general and administrative 7,731,972 7,468,724 Research and development 88,621 246,551 Depreciation and amortization 306,562 296,182 Total Operating Expenses 8,127,155 8,011,457 Net Operating Profit/(Loss) 1,140,952 (330,562 ) Non-Operating (Income)/Expense Interest expense — 5,298 (Income)/loss on foreign currency exchange (65,651 ) 37,594 Other expense and interest income, net (3,743 ) (2,545 ) INCOME (LOSS) BEFORE TAXES 1,210,346 (370,909 ) Income Tax (Expense) Benefit (390,799 ) 154,786 NET INCOME (LOSS) $ 819,547 (216,123 ) NET INCOME (LOSS) PER SHARE Basic $ 0.02 $ (0.01 ) Diluted $ 0.02 $ (0.01 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic 37,873,755 37,877,463 Diluted 38,393,836 37,925,082

SELECTED FINANCIAL RESULTS


For the Ten Months Ended December 31, 2017 For the Twelve Months Ended February 28, 2017 NET SALES $ 13,313,894 $ 12,293,655 Cost of goods sold 5,174,946 4,724,097 Gross Profit 8,138,948 7,569,558 OPERATING EXPENSES Selling, general and administrative 6,594,570 7,767,712 Research and development 50,587 237,486 Depreciation and amortization 257,257 300,611 Total Operating Expenses 6,902,414 8,305,809 Net Operating Profit/(Loss) 1,236,534 (736,251 ) Non-Operating (Income)/Expense Interest expense — 1,886 (Income)/loss on foreign currency exchange (68,566 ) 41,499 Other expense and interest income, net (2,420 ) (2,937 ) INCOME (LOSS) BEFORE TAXES 1,307,520 (776,699 ) Income Tax (Expense) Benefit (402,563 ) 241,700 NET INCOME (LOSS) $ 904,957 $ (534,999 ) NET INCOME (LOSS) PER SHARE Basic $ 0.02 $ (0.01 ) Diluted $ 0.02 $ (0.01 ) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic 37,897,632 37,830,581 Diluted 38,445,482 37,878,201

SOURCE: Repro Med Systems, Inc.

ReleaseID: 489154

"/> RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017 « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
Great News! MarketersMedia is officially entering into a long-term partnership with Vertical News Network.
Learn More
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017

RMS Medical Products Announces Results for Three, Ten and Twelve Months Ending December 31, 2017

Share This Press Release

- Highest Reported Twelve Month Net Sales and Net Income in RMS History
- Double-Digit Percentage Growth in Net Sales
- Increased Profitability

CHESTER, NY / ACCESSWIRE / February 13, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced the latest financial results for the three, ten and twelve months ending December 31, 2017.

The selected financial results encompass the periods since the Company's fiscal year ending on February 28, 2017. To facilitate a period-to-period comparison despite the change in the Company's fiscal year, the selected financial results also include the three and twelve-month periods ending December 31, 2017 and 2016.

Highlights Three Months Ending December 31, 2017 versus 2016

44% Increase in Net Sales
39% Increase in Gross Profit
14% Decrease in Operating Expenses as % of Net Sales
10% Increase in Net Income as % of Net Sales

For the Three Months Ended
December 31,

2017

2016

$ Change

% Change

Net Sales

$
4,125,480

$
2,871,142

$
1,254,338

43.7
%

Gross Profit

$
2,490,196

$
1,790,629

$
699,567

39.1
%

Gross Profit as % of Net Sales

60.4
%

62.4
%

-2.0
%

Operating Expenses

$
2,138,022

$
1,878,810

$
259,212

13.8
%

Operating Expenses as % of Net Sales

51.8
%

65.4
%

-13.6
%

Net Income

$
278,370

$
(90,492
)

$
368,862

N/A

Net Income as % of Net Sales

6.7
%

-3.2
%

9.9
%

Highlights Twelve Months Ending December 31, 2017 versus 2016

25% Increase in Net Sales
21% Increase in Gross Profit
12% Decrease in Operating Expenses as % of Net Sales
7% Increase in Net Income as % of Net Sales

For the Twelve Months Ended
December 31,

2017

2016

$ Change

% Change

Net Sales

$
15,442,712

$
12,364,285

$
3,078,427

24.9
%

Gross Profit

$
9,268,107

$
7,680,895

$
1,587,212

20.7
%

Gross Profit as % of Net Sales

60.0
%

62.1
%

-2.1
%

Operating expenses

$
8,127,155

$
8,011,457

$
115,698

1.4
%

Operating expenses as % of Net Sales

52.6
%

64.8
%

-12.2
%

Net Income

$
819,547

$
(216,123
)

$
1,035,670

N/A

Net Income as % of Net Sales

5.3
%

-1.7
%

7.0
%

Growth in net sales in 2017 was driven principally by increased volume with our existing customers domestically and internationally in all major product categories. The launch of a new drug generated increased needle sales and we believe the new 510(k) clearance by the FDA for the RMS "Integrated Catch-Up Freedom Syringe Drive Infusion System" on August 31, 2017, which includes specific clearance for Cuvitru® and Hizentra®, also contributed in part to increased sales. Internationally, we gained business in several new countries, a current distributor has expanded its home infusion business, and facilitated subcutaneous immunoglobulin gained traction in Europe. Also contributing to the 2017 increase was a backlog at December 31, 2016 of $0.3 million, which was filled during the current period. Excluding this backlog, net sales grew 20.2% for the twelve month period ending December 31, 2017.

The increase in gross profit was driven by the increase in net sales, which was partially offset by the increase in higher salary and related benefits costs from overtime and the addition of a second shift to meet increased demand. Furthermore, increased scrap during quality inspections also negatively impacted gross profit and the gross margin. In January 2018, we implemented a nondestructive testing protocol to reduce scrap.

Andy Sealfon, RMS Chief Executive Officer commented, "I am so pleased to announce that due to the outstanding performance and expanded market acceptance of our FREEDOM Syringe Infusion System, as well as the confirmation by the FDA of the unique technology supporting the use of our system for subcutaneous medications including Hizentra® and Cuvitru®, as well as for intravenous uses such as antibiotics, we experienced our best year ever in the Company's history for net sales and profitability. With new markets opening, planned introduction of new products this year, multiple new clinical trials underway, and international market expansions, we believe we are well positioned for future growth."

For consistency in disclosure presented in our Form 10-K for the period ending December 31, 2017 as required by SEC regulations, we are providing a presentation of the ten months ending December 31, 2017 versus twelve months ending February 28, 2017 as a result of our fiscal year end change. The variations in this presentation are due to the comparison of a ten month period versus a twelve month period. However, net sales in the ten month period were higher than the twelve month period, also due to volume increases with our existing customers domestically and internationally in all major product categories for the same reasons stated above. See Selected Financial Results attached.

About RMS Medical Products

The Company manufactures medical products used for home infusions and suctioning. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.

The Company's website may be visited at www.rmsmedicalproducts.com.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms term "believe" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. The results of operations for the periods presented herein are not necessarily indicative of the results to be expected in the future.

For more information, please call:

Mike King
702 650 3000
Princeton Research

SELECTED FINANCIAL RESULT

For the Three Months Ended
December 31,

2017

2016

NET SALES

$
4,125,480

$
2,871,142

Cost of goods sold

1,635,284

1,080,513

Gross Profit

2,490,196

1,790,629

OPERATING EXPENSES

Selling, general and administrative

2,057,616

1,742,701

Research and development

3,023

52,315

Depreciation and amortization

77,383

83,794

Total Operating Expenses

2,138,022

1,878,810

Net Operating Profit/(Loss)

352,174

(88,181
)

Non-Operating (Income)/Expense

Interest expense

1,930

(Income)/loss on foreign currency exchange

(3,487
)

46,820

Other expense and interest income, net

(1,316
)

(323
)

INCOME (LOSS) BEFORE TAXES

356,977

(136,608
)

Income Tax (Expense) Benefit

(78,607
)

46,116

NET INCOME (LOSS)

$
278,370

$
(90,492
)

NET INCOME (LOSS) PER SHARE

Basic

$
0.01

$
0.00

Diluted

$
0.01

$
0.00

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic

37,994,298

37,754,723

Diluted

38,649,178

37,802,342

SELECTED FINANCIAL RESULTS

For the Twelve Months Ended
December 31,

2017

2016

NET SALES

$
15,442,712

$
12,364,285

Cost of goods sold

6,174,605

4,683,390

Gross Profit

9,268,107

7,680,895

OPERATING EXPENSES

Selling, general and administrative

7,731,972

7,468,724

Research and development

88,621

246,551

Depreciation and amortization

306,562

296,182

Total Operating Expenses

8,127,155

8,011,457

Net Operating Profit/(Loss)

1,140,952

(330,562
)

Non-Operating (Income)/Expense

Interest expense

5,298

(Income)/loss on foreign currency exchange

(65,651
)

37,594

Other expense and interest income, net

(3,743
)

(2,545
)

INCOME (LOSS) BEFORE TAXES

1,210,346

(370,909
)

Income Tax (Expense) Benefit

(390,799
)

154,786

NET INCOME (LOSS)

$
819,547

(216,123
)

NET INCOME (LOSS) PER SHARE

Basic

$
0.02

$
(0.01
)

Diluted

$
0.02

$
(0.01
)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic

37,873,755

37,877,463

Diluted

38,393,836

37,925,082

SELECTED FINANCIAL RESULTS

For the Ten
Months Ended
December 31,
2017

For the Twelve
Months Ended
February 28,
2017

NET SALES

$
13,313,894

$
12,293,655

Cost of goods sold

5,174,946

4,724,097

Gross Profit

8,138,948

7,569,558

OPERATING EXPENSES

Selling, general and administrative

6,594,570

7,767,712

Research and development

50,587

237,486

Depreciation and amortization

257,257

300,611

Total Operating Expenses

6,902,414

8,305,809

Net Operating Profit/(Loss)

1,236,534

(736,251
)

Non-Operating (Income)/Expense

Interest expense

1,886

(Income)/loss on foreign currency exchange

(68,566
)

41,499

Other expense and interest income, net

(2,420
)

(2,937
)

INCOME (LOSS) BEFORE TAXES

1,307,520

(776,699
)

Income Tax (Expense) Benefit

(402,563
)

241,700

NET INCOME (LOSS)

$
904,957

$
(534,999
)

NET INCOME (LOSS) PER SHARE

Basic

$
0.02

$
(0.01
)

Diluted

$
0.02

$
(0.01
)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic

37,897,632

37,830,581

Diluted

38,445,482

37,878,201

SOURCE: Repro Med Systems, Inc.

ReleaseID: 489154

- Highest Reported Twelve Month Net Sales and Net Income in RMS History
- Double-Digit Percentage Growth in Net Sales
- Increased Profitability

CHESTER, NY / ACCESSWIRE / February 13, 2018 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced the latest financial results for the three, ten and twelve months ending December 31, 2017.

The selected financial results encompass the periods since the Company's fiscal year ending on February 28, 2017. To facilitate a period-to-period comparison despite the change in the Company's fiscal year, the selected financial results also include the three and twelve-month periods ending December 31, 2017 and 2016.

Highlights Three Months Ending December 31, 2017 versus 2016

44% Increase in Net Sales
39% Increase in Gross Profit
14% Decrease in Operating Expenses as % of Net Sales
10% Increase in Net Income as % of Net Sales

For the Three Months Ended
December 31,

2017

2016

$ Change

% Change

Net Sales

$
4,125,480

$
2,871,142

$
1,254,338

43.7
%

Gross Profit

$
2,490,196

$
1,790,629

$
699,567

39.1
%

Gross Profit as % of Net Sales

60.4
%

62.4
%

-2.0
%

Operating Expenses

$
2,138,022

$
1,878,810

$
259,212

13.8
%

Operating Expenses as % of Net Sales

51.8
%

65.4
%

-13.6
%

Net Income

$
278,370

$
(90,492
)

$
368,862

N/A

Net Income as % of Net Sales

6.7
%

-3.2
%

9.9
%

Highlights Twelve Months Ending December 31, 2017 versus 2016

25% Increase in Net Sales
21% Increase in Gross Profit
12% Decrease in Operating Expenses as % of Net Sales
7% Increase in Net Income as % of Net Sales

For the Twelve Months Ended
December 31,

2017

2016

$ Change

% Change

Net Sales

$
15,442,712

$
12,364,285

$
3,078,427

24.9
%

Gross Profit

$
9,268,107

$
7,680,895

$
1,587,212

20.7
%

Gross Profit as % of Net Sales

60.0
%

62.1
%

-2.1
%

Operating expenses

$
8,127,155

$
8,011,457

$
115,698

1.4
%

Operating expenses as % of Net Sales

52.6
%

64.8
%

-12.2
%

Net Income

$
819,547

$
(216,123
)

$
1,035,670

N/A

Net Income as % of Net Sales

5.3
%

-1.7
%

7.0
%

Growth in net sales in 2017 was driven principally by increased volume with our existing customers domestically and internationally in all major product categories. The launch of a new drug generated increased needle sales and we believe the new 510(k) clearance by the FDA for the RMS "Integrated Catch-Up Freedom Syringe Drive Infusion System" on August 31, 2017, which includes specific clearance for Cuvitru® and Hizentra®, also contributed in part to increased sales. Internationally, we gained business in several new countries, a current distributor has expanded its home infusion business, and facilitated subcutaneous immunoglobulin gained traction in Europe. Also contributing to the 2017 increase was a backlog at December 31, 2016 of $0.3 million, which was filled during the current period. Excluding this backlog, net sales grew 20.2% for the twelve month period ending December 31, 2017.

The increase in gross profit was driven by the increase in net sales, which was partially offset by the increase in higher salary and related benefits costs from overtime and the addition of a second shift to meet increased demand. Furthermore, increased scrap during quality inspections also negatively impacted gross profit and the gross margin. In January 2018, we implemented a nondestructive testing protocol to reduce scrap.

Andy Sealfon, RMS Chief Executive Officer commented, "I am so pleased to announce that due to the outstanding performance and expanded market acceptance of our FREEDOM Syringe Infusion System, as well as the confirmation by the FDA of the unique technology supporting the use of our system for subcutaneous medications including Hizentra® and Cuvitru®, as well as for intravenous uses such as antibiotics, we experienced our best year ever in the Company's history for net sales and profitability. With new markets opening, planned introduction of new products this year, multiple new clinical trials underway, and international market expansions, we believe we are well positioned for future growth."

For consistency in disclosure presented in our Form 10-K for the period ending December 31, 2017 as required by SEC regulations, we are providing a presentation of the ten months ending December 31, 2017 versus twelve months ending February 28, 2017 as a result of our fiscal year end change. The variations in this presentation are due to the comparison of a ten month period versus a twelve month period. However, net sales in the ten month period were higher than the twelve month period, also due to volume increases with our existing customers domestically and internationally in all major product categories for the same reasons stated above. See Selected Financial Results attached.

About RMS Medical Products

The Company manufactures medical products used for home infusions and suctioning. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, RMS Precision Flow Rate Tubing™ and RMS HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in professional healthcare settings as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers in addition to a variety of other healthcare providers.

The Company's website may be visited at www.rmsmedicalproducts.com.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms term "believe" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission. The results of operations for the periods presented herein are not necessarily indicative of the results to be expected in the future.

For more information, please call:

Mike King
702 650 3000
Princeton Research

SELECTED FINANCIAL RESULT

For the Three Months Ended
December 31,

2017

2016

NET SALES

$
4,125,480

$
2,871,142

Cost of goods sold

1,635,284

1,080,513

Gross Profit

2,490,196

1,790,629

OPERATING EXPENSES

Selling, general and administrative

2,057,616

1,742,701

Research and development

3,023

52,315

Depreciation and amortization

77,383

83,794

Total Operating Expenses

2,138,022

1,878,810

Net Operating Profit/(Loss)

352,174

(88,181
)

Non-Operating (Income)/Expense

Interest expense

1,930

(Income)/loss on foreign currency exchange

(3,487
)

46,820

Other expense and interest income, net

(1,316
)

(323
)

INCOME (LOSS) BEFORE TAXES

356,977

(136,608
)

Income Tax (Expense) Benefit

(78,607
)

46,116

NET INCOME (LOSS)

$
278,370

$
(90,492
)

NET INCOME (LOSS) PER SHARE

Basic

$
0.01

$
0.00

Diluted

$
0.01

$
0.00

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic

37,994,298

37,754,723

Diluted

38,649,178

37,802,342

SELECTED FINANCIAL RESULTS

For the Twelve Months Ended
December 31,

2017

2016

NET SALES

$
15,442,712

$
12,364,285

Cost of goods sold

6,174,605

4,683,390

Gross Profit

9,268,107

7,680,895

OPERATING EXPENSES

Selling, general and administrative

7,731,972

7,468,724

Research and development

88,621

246,551

Depreciation and amortization

306,562

296,182

Total Operating Expenses

8,127,155

8,011,457

Net Operating Profit/(Loss)

1,140,952

(330,562
)

Non-Operating (Income)/Expense

Interest expense

5,298

(Income)/loss on foreign currency exchange

(65,651
)

37,594

Other expense and interest income, net

(3,743
)

(2,545
)

INCOME (LOSS) BEFORE TAXES

1,210,346

(370,909
)

Income Tax (Expense) Benefit

(390,799
)

154,786

NET INCOME (LOSS)

$
819,547

(216,123
)

NET INCOME (LOSS) PER SHARE

Basic

$
0.02

$
(0.01
)

Diluted

$
0.02

$
(0.01
)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic

37,873,755

37,877,463

Diluted

38,393,836

37,925,082

SELECTED FINANCIAL RESULTS

For the Ten
Months Ended
December 31,
2017

For the Twelve
Months Ended
February 28,
2017

NET SALES

$
13,313,894

$
12,293,655

Cost of goods sold

5,174,946

4,724,097

Gross Profit

8,138,948

7,569,558

OPERATING EXPENSES

Selling, general and administrative

6,594,570

7,767,712

Research and development

50,587

237,486

Depreciation and amortization

257,257

300,611

Total Operating Expenses

6,902,414

8,305,809

Net Operating Profit/(Loss)

1,236,534

(736,251
)

Non-Operating (Income)/Expense

Interest expense

1,886

(Income)/loss on foreign currency exchange

(68,566
)

41,499

Other expense and interest income, net

(2,420
)

(2,937
)

INCOME (LOSS) BEFORE TAXES

1,307,520

(776,699
)

Income Tax (Expense) Benefit

(402,563
)

241,700

NET INCOME (LOSS)

$
904,957

$
(534,999
)

NET INCOME (LOSS) PER SHARE

Basic

$
0.02

$
(0.01
)

Diluted

$
0.02

$
(0.01
)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic

37,897,632

37,830,581

Diluted

38,445,482

37,878,201

SOURCE: Repro Med Systems, Inc.

ReleaseID: 489154

Source URL: https://marketersmedia.com/rms-medical-products-announces-results-for-three-ten-and-twelve-months-ending-december-31-2017/300542

Source: AccessWire

Release ID: 300542

Latest Releases


Fatal error: Call to undefined function related_posts() in /home/marketer/public_html/wp-content/themes/mm/single-content.php on line 211